Signature Global to Launch IPO on September 20
Signature Global, an NCR-based real estate company catering to affordable and mid-priced housing, is set to launch its initial public offering (IPO) on September 20. The company has a fresh issue of ₹603 crore and an offer-for-sale of ₹127 crore from the International Finance Corporation (IFC). The price band is set at ₹366–₹385 per share. The issue will close on September 22.
The company’s sales were at ₹3,430.6 crore in FY23, growing at a compound annual growth rate (CAGR) of 42% between FY21 and FY23. It currently has ongoing projects for 2.13 crore sq.ft. of developable area and forthcoming projects for 2.45 crore sq.ft. of developable area.
Signature Global is yet to become profitable, making a loss of ₹56 crore in FY23. However, some of its projects are making profits, said Chief Executive Officer Rajat Kathuria.
Post-listing, the promoter shareholding will be around 70%. Currently, the promoter shareholding is at 78% of the total shareholding. No promoter is selling their stakes in the company.
The company is targeting to raise ₹730 crore through the IPO, which will be used to fund its ongoing and upcoming projects. The IPO is being managed by Kotak Mahindra Capital Company, JM Financial, and Axis Capital.
Signature Global is confident of achieving its target of becoming among the top-five real estate players in India in the next few years. The management said that they are well-positioned to capitalize on the growing demand for affordable and mid-priced housing in India.
The company has a strong track record of execution, with a portfolio of over 100 projects across NCR, Pune, and Bengaluru. It has a team of over 1,000 professionals and is committed to providing quality homes to its customers.
The IPO is expected to be well-received by investors, given the company’s strong fundamentals and growth potential.
Related News
- 22 Sep
Samhi Hotels Stock Lists with 6.75% Premium, Analysts Recommend Booking Profits
Samhi Hotels stock made a weak debut on the stock exchanges, listing at a premium of just 6.75% over the IPO price. Several analysts have recommended booking profits in the stock, citing its loss-making status and negative net worth.
- 22 Sep
Signature Global IPO Subscribed 11.88 Times on Final Day
The Signature Global IPO was subscribed 11.88 times on the final day of bidding. The company will use the proceeds to repay debt and for land acquisitions and general corporate purposes. The IPO is expected to list on October 4, but this may change due to the new timeline of T+3.
- 22 Sep
Sai Silks IPO Oversubscribed 4.4 Times on Final Day of Bidding
Sai Silks IPO was oversubscribed 4.4 times on the final day of bidding, with qualified institutional buyers and high networth individuals supporting the issue on closing day. The net fresh issue proceeds will be utilized by the company mainly for the setting up of 30 new stores, two warehouses, working capital requirements and repaying debts. The trading in its equity shares will commence with effect from October 4, as per the IPO schedule.
- 22 Sep
Pharma company Valiant Laboratories to go public on September 27
Pharma company Valiant Laboratories is going public on September 27 at a price band of Rs 133-140 per share. The company plans to raise Rs 152.46 crore via the IPO. Proceeds will be used to fund the expenditure for setting up a manufacturing facility for speciality chemicals and for working capital requirements and general corporate purposes. Valiant Laboratories is a Mumbai-based API and bulk drug manufacturing company with a focus on Paracetamol. It is owned by the promoters including Dhanvallabh Ventures LLP, which holds 62.5 percent shareholding. Valiant Organics, the listed entity on the BSE and NSE, is the promoter of Dhanvallabh Ventures LLP with 73.15 percent stake.
- 21 Sep
Unihealth Consultancy makes tepid debut on NSE Emerge
Unihealth Consultancy, a healthcare service provider, made a tepid debut on the NSE Emerge platform on September 21, listing at Rs 135, a 2.2 percent premium over its issue price of Rs 132. The stock was trading at Rs 137.30 at 11.40 am. The company has a number of positives going for it, such as its strong growth potential, its diversified business model, and its focus on the African market. However, investors who are considering investing in Unihealth Consultancy should carefully consider the company's fundamentals, the current market conditions, and their own risk appetite before making a decision.
Leave a Reply